Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | FABP3 | P05413 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759203 | 0.82 | FABP3 (0.32) | LMNAFABP3FABP4FABP5 | |
| SCHEMBL12759188 | 0.75 | CYP2A6 (0.35) | CYP2A6LMNA | |
| SCHEMBL12759186 | 0.70 | CCR1 (0.33) | LMNA | |
| SCHEMBL27251652 | 0.69 | CYP2A6 (0.44) | PDE3BPDE3ACYP2A6LMNA | |
| SCHEMBL13233189 | 0.69 | RPS6KA3 (0.36) | PDE3BPDE3ALMNA | |
| SCHEMBL13233190 | 0.69 | ALDH1A1 (0.42) | SLC40A1LMNA | |
| SCHEMBL12832475 | 0.69 | FABP3 (0.32) | PDE3BPDE3AFABP3FABP4FABP5 | |
| SCHEMBL12759204 | 0.68 | KDM4E (0.43) | — | |
| SCHEMBL16769242 | 0.68 | LMNA (0.31) | LMNA | |
| SCHEMBL14265466 | 0.67 | CYP2A6 (0.50) | PDE3BPDE3ACYP2A6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910561-B2 | Cancer; such as 3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridin-5(6H)-one; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080287457-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287457-A1 | Inhibitors of Akt Activity | AKT3, MTOR, STK3 | PDE3B 2096/4885PDE3A 2281/4885CYP2A6 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.